Prospective Study Validates Omnisense Ability to Predict Hip Fracture
San Antonio, Texas (September 20, 2002) - A widely-based prospective study among
institutionalized elderly subjects has demonstrated that the measurement results
provided by Sunlight Omnisense®, a unique ultrasound bone assessment device, can
help in predicting hip fracture rates. This new study, which will be presented at
the ASBMR conference in San Antonio, Texas in September 2002, by Dr. H. Dobnig,
of Karl Franzens University, Graz, Austria, validates the use of Omnisense as a
highly effective tool for osteoporosis management. The device is sold around the
world for osteoporosis and fracture risk assessment, and is currently gaining in
popularity thanks to its unique ability to measure multiple skeletal sites with
its proprietary ultrasound technology.
A large body of clinical evidence has already demonstrated the ability of Omnisense to differentiate between fractured and
non-fractured subjects. Hundreds of physicians worldwide use the device based on these results from cross-sectional studies.
Prospective studies such as the current one take these clinical results a step further by confirming that observed differences
between fractured and non-fractured subjects also occur in the same subjects over time.
In this study, the first in a series of prospective studies with Omnisense, over 1000 female subjects over 70 were followed
for an average of one year. Subjects with lower bone assessment scores at the phalanx or the radius at the start of the study
were significantly more likely to sustain fractures during the course of the study.
"This study demonstrates once again the excellent ability of Omnisense in the prediction of fracture risk," explains Dr. Irit
Yaniv, Sunlight's medical director. "Physicians can use the device to predict fracture risk and prescribe treatment for their
patients, confident that they are providing accurate, precise diagnosis."
Also at the ASBMR conference, a study investigating the applicability of Omnisense T-scores for osteoporosis diagnosis will be
presented. The study concludes that the WHO criteria of a T-score of -2.5 as indicative of osteoporosis is appropriate for
Omnisense measurement at the forearm. Other Omnisense sites require slightly different T-scores. The applicability of this
widely-used criterion for osteoporosis to Omnisense measurement makes use of the Omnisense results simple and convenient for
patient and physician.
Sunlight Medical is an international company with offices in the United States, Germany, China, and Israel.
For more information about Sunlight and the Omnisense 7000S bone sonometer, visit Sunlight's booth (Booth 422) at
the ASBMR conference, contact David Helowicz, National Sales Manager, at (800) 750 6011, ext. 318, or visit
Sunlight's website at www.sunlightmedical.com.
